FDA approves Janssen’s HIV combination Symtuza

Janssen has won US approval for its once-daily HIV pill Symtuza (D/C/F/TAF), which it hopes will improve patient adherence and resistance to treatment. Symtuza (D/C/F/TAF) combines Janssen’s darunavir with Gilead’s cobicistat, emtricitabine and tenofovir alafenamide in a single pill and was licensed for HIV-1 in treatment-naïve and certain virologically suppressed adults. Brian Woodfall, global head of late development, infectious diseases at Janssen Pharmaceutica, said: “The FDA approval of Symtuza marks another important milestone in our quest to address real-world clinical challenges, combat HIV drug resistance and meet the diverse needs of those living with HIV.